PATENT CLAIM ANALYSIS

Application Number: 16029196
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-10
Patent Classification: ["424", "093700"]

Abstract:
The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain light-chain variable (V H /V L ) domain and the heavy chain-light chain constant (C H1 /C L ) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Claim (Index 8):
A method for producing a fragment, antigen binding (Fab) comprising:\n (A) (1) co-expressing in a host cell:\n (a) a first nucleic acid encoding both a heavy chain variable domain and a human IgG heavy chain constant CH1 domain, wherein said heavy chain variable domain comprises a tyrosine at residue 39 and said human IgG heavy chain constant CH1 domain comprises a WT sequence, wherein each of said residues are numbered according to the Kabat numbering system; and \n (b) a second nucleic acid encoding both a light chain variable domain and a light chain constant domain, wherein said light chain variable domain comprises an arginine at residue 38 and said light chain constant domain comprises a WT sequence, wherein each of said residues are numbered according to the Kabat numbering system and wherein each of said heavy chain and light chain variable domains comprise three complementarity determining regions (CDRs) which direct binding to an antigen; \n (2) cultivating said host cell under conditions such that said heavy chain variable and human IgG CH1 constant domains and said light chain variable and constant domains are produced; and (3) recovering from said host cell a Fab wherein said Fab comprises said heavy chain variable and constant domains and said light chain variable and constant domains; (B)(1) co-expressing in a host cell:\n (a) a first nucleic acid encoding both a heavy chain variable domain and a human IgG heavy chain constant CH1 domain, wherein said heavy chain variable domain comprises a tyrosine at residue 39 and said human IgG heavy chain constant CH1 domain comprises a WT sequence, wherein each of said residues are numbered according to the Kabat numbering system; and \n (b) a second nucleic acid encoding both a light chain variable domain and a light chain constant domain, wherein said light chain variable domain comprises an arginine at residue 38 and said light chain constant domain comprises a WT sequence, wherein each of said residues are numbered according to the Kabat numbering system and wherein each of said heavy chain and light chain variable domains comprise three complementarity determining regions (CDRs) which direct binding to an antigen; \n (2) cultivating said host cell under conditions such that said heavy chain variable and human IgG CH1 constant domains and said light chain variable and constant domains are produced; and (3) recovering from said host cell a Fab wherein said Fab comprises said heavy chain variable and constant domains and said light chain variable and constant domains; or (C)(1) co-expressing in a host cell:\n (a) a first nucleic acid encoding both a heavy chain variable domain and a human IgG heavy chain constant CH1 domain, wherein said heavy chain variable domain comprises a tyrosine at residue 39 and said human IgG heavy chain constant CH1 domain comprises an aspartic acid at residue 228, wherein each of said residues are numbered according to the Kabat numbering system; and \n (b) a second nucleic acid encoding both a light chain variable domain and a light chain constant domain, wherein said light chain variable domain comprises an arginine at residue 38 and said light chain constant domain comprises a lysine at residue 122, wherein each of said residues are numbered according to the Kabat numbering system and wherein each of said heavy chain and light chain variable domains comprise three complementarity determining regions (CDRs) which direct binding to an antigen; \n (2) cultivating said host cell under conditions such that said heavy chain variable and human IgG CH1 constant domains and said light chain variable and constant domains are produced; and (3) recovering from said host cell a Fab wherein said Fab comprises said heavy chain variable and constant domains and said light chain variable and constant domains.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14773418', '15501620', '15747385', '15879260', '14816252']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7247568326745063
- 35 USC 102 Novelty (BERT): 0.6342160762087927
- Combined Prediction Score: 0.715702757027935
- Mean Citation Score: 412.253556
- Max Citation Score: 624.28595
- Similarity Product: 532.5173945355267

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test